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The Oct2 protein, encoded by the Pou2f2 gene, was originally predicted to act as a DNA
binding transcriptional activator of immunoglobulin (Ig) in B lineage cells. This prediction
flowed from the earlier observation that an 8-bp sequence, the “octamer motif,” was a
highly conserved component of most Ig gene promoters and enhancers, and evidence from
over-expression and reporter assays confirmed Oct2-mediated, octamer-dependent gene
expression. Complexity was added to the story when Oct1, an independently encoded
protein, ubiquitously expressed from the Pou2f1 gene, was characterized and found to
bind to the octamer motif with almost identical specificity, and later, when the co-activator
Obf1 (OCA-B, Bob.1), encoded by the Pou2af1 gene, was cloned. Obf1 joins Oct2 (and
Oct1) on the DNA of a subset of octamer motifs to enhance their transactivation strength.
While these proteins variously carried the mantle of determinants of Ig gene expression
in B cells for many years, such a role has not been borne out for them by characterization
of mice lacking functional copies of the genes, either as single or as compound mutants.
Instead, we and others have shown that Oct2 and Obf1 are required for B cells to mature
fully in vivo, for B cells to respond to the T cell cytokines IL5 and IL4, and for B cells to
produce IL6 normally during a T cell dependent immune response. We show here that
Oct2 affects Syk gene expression, thus influencing B cell receptor signaling, and that Oct2
loss blocks Slamf1 expression in vivo as a result of incomplete B cell maturation. Upon
IL4 signaling, Stat6 up-regulates Obf1, indirectly via Xbp1, to enable plasma cell differenti-
ation.Thus, Oct2 and Obf1 enable B cells to respond normally to antigen receptor signals,
to express surface receptors that mediate physical interaction with T cells, or to produce
and respond to cytokines that are critical drivers of B cell and T cell differentiation during a
humoral immune response.
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INTRODUCTION
Octamer binding protein 2, or Oct2, is encoded by the Pou2f2 gene.
It was one of the first cell type-specific transcription factors identi-
fied and cloned (1). As indicated by its name, it is a founding mem-
ber of a family of DNA binding proteins concurrently discovered,
that share a conserved bipartite DNA binding domain compris-
ing a homeobox-like domain and a second conserved sequence
entitled the POU domain, for the P it1, Oct1/Oct2, U nc86 pro-
teins (2). Oct2 binds to a conserved consensus DNA sequence,
the “octamer motif” found in the promoters and enhancers of
many genes, including those encoding immunoglobulins (3, 4).
The Obf1 protein encoded by the Pou2af1 gene, which is also
known as OCA-B and Bob.1 was subsequently cloned using a
yeast 1-hybrid screen for B cell proteins that physically interact
with Oct1 or Oct2 (5–7). While Oct1/Oct2 and Obf1 share the
capacity to bind to and activate genes adjacent to octamer motifs,
they are selective in the genes to which they bind. The selectivity of
target gene binding is determined, in part, by the sequence of the
octamer motif, and whether it conforms to one of two classes of
site, designated“PORE”and“MORE”motifs (8). Whether binding
mediates activation or repression is also influenced by the par-
ticipation of cofactors [reviewed by Tantin (9)], including Obf1,
which can potentiate the transactivation potential of Oct1 and
Oct2 (8, 10).
Oct2 is expressed primarily but not exclusively in the B cell
lineage, where it increases with cellular activation (11). Neurons,
macrophages, and T cells have also been shown to express Oct2
(12–18). Oct2 is required for post-natal survival (19), so must
regulate critically important genes outside of the immune system.
These will not be discussed here. The Oct2 gene is large, displays
complex splicing patterns, and encodes protein isoforms with mul-
tiple essential activation domains (20–22). Oct2 is largely localized
to the nucleus. Obf1 expression is mostly restricted to B lineage
cells, where it is also highly induced upon activation (23). Zwilling
et al. (24) have reported expression in T cells, but myeloid cells do
not express Obf1 (15). A small protein of ~35 kDa, Obf1 is found in
both the nucleus and cytoplasm, where a proportion may be teth-
ered to the cell membrane after post-translational myristoylation
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(25), and a potential role for membrane-associated Obf1 in B cell
receptor (BCR) signaling has been proposed (26).
A series of studies have shown that Oct2 and Obf1 are required
for full functional and phenotypic maturation of B cells. In single
knockout (KO) mice of each gene, peripheral B cells are numeri-
cally reduced and display some features of immature transitional
cells (27, 28). The peritoneal B1 and splenic marginal zone (MZ)
populations are missing in Oct2−/− mice (27, 29). Obf1−/− mice
are viable and fertile, but show B cell developmental defects (30,
31), have an expanded B1 cell population (32). They also lack
MZ B cells (33) and completely fail to produce germinal centers
(GCs), the sites of cognate B cell:T cell interaction and expan-
sion, upon immunization, or infection (34–37). Both Oct2- and
Obf1-deficient splenic B cells display aberrant responses to BCR
signaling and other characteristics of immature B cells (27, 34,
38). Oct2-deficient B cells also fail to respond to lipopolysac-
charide (LPS), which signals through TLR4 (38). In vivo, serum
immunoglobulin (Ig) levels in both mutants, particularly those
that are T cell dependent, are strongly reduced (34–36, 38). Mice
doubly deficient for Oct2 and Obf1 show a stronger humoral
deficiency phenotype, reflecting the distinct activities of the two
factors, but still express Ig genes (39). Thus, the two factors are
not required, singly or in combination, for Ig gene expression by
B cells.
Detailed functional studies on Oct2- and Obf1-deficient B cells
in vitro and in vivo have identified a number of genes regulated by
the two factors. Oct2 directly regulates the gene encoding CD36,
a class B scavenger receptor family (40), but only in B cells, not
in macrophages or dendritic cells (41–43). However, no role for
CD36 in B cells has been determined (44). Oct2-deficent B cells
have been shown to be defective in their responses to the T cell
cytokine IL5 as a result of the direct regulation of the Cd125 gene
encoding the IL5Rα chain (29). IL5 promotes antibody-secreting
cell (ASC) differentiation in mouse B cells (45), and Oct2−/− B
cells are defective in this process (29). In another study, it was
shown that both Oct2 and Obf1 contribute to the regulation of
IL6 production by activated B cells, through direct effects, at least
by Oct2, on the Il6 gene (11). As Obf1 does not contact DNA (5),
it is difficult using current procedures to prove direct interaction
of Obf1 with putative target gene loci. IL6 is important during T
follicular helper (Tfh) cell polarization (46). We have also shown,
using the same quantitative tools that identified the role of Oct2
and IL5 in ASC differentiation, that Obf1 is required for T cell
dependent ASC differentiation, but not isotype switching, both
in vitro and in vivo (29).
In addition to these established roles for Oct2 and Obf1 in
B cells, we include below data from studies on other genes that
we have found to be differentially regulated in Oct2- and Obf1-
deficient B cells. These include the genes encoding the Syk protein,
which is an important transducer of BCR signals and Slamf1, an
essential mediator of cell:cell contact, especially in the context of
a developing GC. Expression of Syk and Slamf1 are sensitive to
Oct2 loss, through different mechanisms. We also show that Obf1
is downstream of Stat6 in the IL4 signaling pathway of B cells, with
Xbp1, another Stat6 target, its direct activator. We include these
data to add to our understanding of the valuable roles that Oct2
and Obf1 play in B cell responses to antigen and to T cell help.
RESULTS
Consistent with their distinct roles in vivo, Oct2 and Obf1 have
quite distinct patterns of expression in peripheral B cells, as mea-
sured by RNAseq of sorted populations from naive C57BL/6 mice
(Figure 1A). Oct2 levels are highest in B1 cells of the peritoneal
cavity, and decline with terminal differentiation to ASCs. In con-
trast, Obf1 levels peak in GC B cells, which require Obf1 for their
generation, and remain high in ASC. For contrast, expression of
Syk and Slamf1 in the same populations are shown in Figure 1A, as
these two genes are influenced directly and indirectly, respectively,
by Oct2, and will be discussed below.
Oct2 MODULATES B CELL RECEPTOR SIGNALING BY FINE-TUNING Syk
EXPRESSION
A microarray screen for Oct2-dependent genes identified the tyro-
sine kinase Syk as a potential target gene. Characterization of the
murine Syk promoter using 5′ RACE identified two alternative
transcriptional initiation sites (Figure 1B) that append alternative
5′ non-coding exons to Syk mRNAs in B cells. Both transcripts
encode the same protein, as the start of Syk translation lies in
an exon common to the two transcripts. RNAseq data for Syk in
sorted B cell populations show that the usage of exons 1 or 2 varies
subtly among them (Figure 1C).
The promoter upstream of exon 2 is positively regulated by
Oct2. B cells sorted from Oct2−/− mice (Figure 2A) have a lower
level of Syk transcripts and protein than wild type (WT) mice
(Figures 2B,C). Using qPCR to distinguish Syk transcripts derived
from exon 1 or exon 2, we found that those derived from exon 2
were selectively reduced in Oct2−/− B cells (Figure 2D). To con-
firm the influence of Oct2 on the Syk exon 2 promoter, we stably
introduced an estradiol-inducible form of Oct2 (29) into a cloned
Oct2−/− B lymphoma cell line, OM1 (48). Upon treatment with
estradiol, there was no effect on expression from exon 1 with either
the vector only control or the inducible Oct2 construct. However,
estradiol induction of Oct2 selectively enhanced Syk expression
from exon 2 and culminated in markedly increased Syk mRNA
levels (Figures 2E,F). A DNA sequence search revealed three per-
fect consensus octamer sequences in the Syk gene (Figure 1B).
Chromatin immunoprecipitation (ChIP) of Oct2 on DNA from
the WT B lymphoma WEHI231 showed strong enrichment of
DNA from the promoter of the known Oct2 target gene Cd36
(Figure 2G). The DNA adjacent to the perfect octamer sequence
upstream of exon 2 was also significantly enriched in the ChIP,
but adjacent sequences in intron 1/2 were not. Thus, Oct2 can
directly increase Syk levels in B cells, acting at one of two alternative
promoters.
As mentioned above, Oct2 is required for the full functional and
phenotypic maturation of B cells, such that peripheral B cells in
Oct2−/− mice are numerically reduced and display some features
of immature transitional cells, and the B1 and MZ populations are
missing (27, 29, 38). Like transitional B cells, Oct2-deficient B cells
are killed rather that activated by BCR cross-linking [Ref. (38, 49);
see also Figure 3A]. However, Oct2−/− B cells respond normally
to the survival factor Baff/BlyS, and survive to expand normally
when BCR signaling occurs in the presence of Baff (Figures 3A,B
and data not shown). Oct2−/− mice expressing a Bcl2 transgene
still lack B1 and MZ B cells (data not shown). Thus abnormal
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FIGURE 1 | Expression of Oct2, Obf1, Syk, and Slamf1 in peripheral B cell
populations. (A) RNAseq data measuring expression of Oct2/Pou2f2,
Obf1/Pou2af1, Syk, and Slamf1 in B cell populations sorted ex vivo from naïve
C57BL/6 mice. FoB, follicular B cells from spleen (small B220+, IgM+, IgD+)
PerB1 and PerB2, B220+ cells from peritoneal lavages of naïve mice, stained
with CD23 and Mac1. B1 cells were CD23− and Mac1lo and B2 cells were
CD23+ and Mac1−; MZB, splenic marginal zone B cells, B220+, IgMhi, CD21hi;
GCB, germinal center B cells (B220+, Fas+, GL7+) from spleens of mice
immunized 8 days previously with SRBC; ASC, antibody-secreting cells sorted
as syndecan1+, GFP+ cells from spleens (Spl), and bone marrows (BM) of
mice carrying the Blimp-GFP reporter gene (47). Data were derived from at
least two independent biological replicates in all cases. Because Ig
sequences can represent >70% of the RNA from plasma cells (data not
shown), the RNAseq data shown in the figure excludes all reads mapping to
the Ig (heavy and light chain) loci as described in Section “Materials and
Methods.” (B) Structure of the mouse Syk gene, showing exons, alternative
transcriptional start sites (small arrows), the locations of a
(Continued)
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FIGURE 1 | Continued
perfect consensus octamer motif (*) and the positions of PCR primers used
here. Filled boxes indicate protein coding sequence, and open boxes,
sequence comprising the 5′ and 3′ untranslated regions of Syk mRNA. (C)
RNAseq tracks showing expression of the Syk gene exons in different sorted
B cell populations, normalized to library size, and aligned with the gene
structure of (B). Note that exon 1, as shown in this panel, is not included in
the RefSeq (Mouse mm9, July 2007) map of Syk mRNA, but is represented
in alternate Syk transcripts ENSMUST00000120135 and
ENSMUST00000118756 in the Ensembl database.
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FIGURE 2 | Oct2 directly and selectively activates transcription from
Syk exon 2. (A) Splenic B cells from WT and Oct2 KO mice stained for
B220 and IgD expression and sorted for phenotypically mature Fo B cells.
(B) Syk RNAseq data from WT (black bars) and Oct2−/− (gray bars) B cells,
sorted as in (A), activated for 48 h with CpG or anti-CD40. (C) Syk protein in
sorted resting Fo B cells from Oct2+ /+ or Oct2−/− mice. (D) qPCR of Syk
mRNA distinguishing transcripts initiated at exons 1 or 2 in sorted splenic
Fo B from WT and Oct2 KO mice. Expression is relative to that of the hmbs
housekeeping gene. Values are means±SD of triplicate assays. (E) Specific
induction of transcription from Syk exon 2 upon Oct2 over-expression in
OM1 cells, which are Oct2−/− (48), as shown by qPCR. Values are
means±SD of triplicates. (F) Northern blot for total Syk mRNA from a
parallel experiment. (G) Quantitation of Oct2 chromatin
immunoprecipitation (ChIP) qPCR data, showing enrichment of the Cd36
promoter [a known Oct2 target gene (41, 42)] and Syk sequences upstream
of exon 2. Oct2:DNA complexes were precipitated from WEHI231 B
lymphoma cells (which are Oct2+ /+) and OM1 B lymphoma cells. Oct2 does
not bind appreciatively to adjacent sequences in Syk intron 1/2. Values are
means±SD of triplicate assays. P values were calculated using the
unpaired Student’s t -test; NS, not significant.
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FIGURE 3 | Oct2 is required for normal signaling from the B cell
receptor, and ectopic Syk expression enhances the response in both WT
and KO B cells. (A) B cell proliferation in response to BCR signaling, Baff, or
both in combination after 3 days. Stimulation index is calculated as
proliferation relative to unstimulated cells. Filled bars, Oct2+ /+ gray bars,
Oct2−/−. All values are the mean of triplicates±SD. (B) Survival, assessed by
propidium iodide exclusion, of B cells cultured with Baff or with anti-µ for
3 days. Filled bars, Oct2+ /+ gray bars, Oct2−/−. All values are the mean of
triplicates±SD. (C) Syk protein levels in cloned B lymphoma cells
transduced with a Syk-expressing retrovirus. The Oct2+ /+ and Oct2−/− cell
lines are BC1 and OM1, respectively (48). (D) Cytometric measurement of
Ca2+ flux in clones of BC1 and OM1 cells transduced with vector only
(black) or a Syk-expressing retrovirus (red). The arrow indicates the timing of
addition of anti-µ to cross-link the BCR. (E) Primary splenic B cells from
Oct2+ /+ and Oct2−/− mice were activated, transduced (see Materials and
Methods) and subsequently treated with anti-µ. The number of live,
transduced (GFP+) cells in each culture after 48 h is shown. Values are
means (n=4)±SD. Filled bars, Oct2+ /+ gray bars, Oct2−/−.
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survival properties are not responsible for the lack of these two
populations in the Oct2 mutant mice.
We speculated that the reduced Syk levels in Oct2−/− B cells
might contribute to their failure to mature in vivo and respond to
BCR signals in vitro. We constructed a retroviral vector expressing
Syk, and infected and cloned WT (BC1) and Oct2-deficient (OM1)
lymphoma cells (Figure 3C). Boosting Syk protein levels enhanced
the BCR response, as measured by calcium flux, in both WT and
Oct2−/− cells (Figure 3D). Finally, using transduction of primary
B cells (see Materials and Methods), we found that elevating Syk
levels improved the proliferation of WT B cells, both unstimulated,
and more strongly, upon BCR cross-linking, and that Oct2−/− B
cells complemented with Syk retrovirus were activated to expand,
rather than be killed by a BCR signal (Figure 3E). The rescue was
not complete, as cell survival was still lower overall in the mutant
cell cultures. This is likely to reflect technical limitations of the
assay, including comparative infectivity of WT and mutant cells,
and the correct timing of exogenous Syk expression in the con-
text of the BCR signal. However, the results strongly suggest that
Syk levels are limiting in Oct2−/− and, to a lesser extent, in WT B
cells. We propose that Oct2 regulates Syk gene expression to enable
positive selection through the BCR and therefore entrance to the
mature follicular B cell pool, and it may similarly enable differen-
tiation of B1 and MZ B cells, which are highly dependent on BCR
signal strength.
Oct2 INDIRECTLY AND SELECTIVELY REGULATES Slamf1 EXPRESSION
ON B CELLS
Slamf1 encodes CD150, a lymphocyte signaling and adhesion mol-
ecule (50) that is expressed in B cells and T cells and at very
low levels in myeloid cells (see www.immgen.org). Our RNAseq
analysis of activated B cells indicated that Slamf1 was expressed
at abnormally low levels in Oct2 KO B compared to controls
(Figure 4A). This was confirmed by flow cytometric analysis
(Figure 4B). Resting WT and LPS-activated B cells expressed sim-
ilar levels of Slamf1, but levels on Oct2-deficient B cells were much
lower than controls under both conditions. Activated WT T cells
up-regulated Slamf1 from resting levels. However, Slamf1 was not
Oct2-dependent in resting or activated T cells, or in macrophages
expanded from fetal liver, despite Oct2 normally being expressed
in these cell types (15, 16, 18).
We next asked whether Slamf1 was a direct Oct2 target using
cloned WT (WEHI231) and KO (OM1) B lymphoma lines trans-
duced with the inducible Oct2-ER vector, as described above. As
expected, the Oct2 target Cd36 gene was expressed in WEHI231
but not OM1 (Figure 4C). Estradiol treatment enhanced Cd36 lev-
els in WEHI231, and strongly induced Cd36 expression in OM1
cells. However, Slamf1 expression, while low in the Oct2−/− line,
was not increased by Oct2 induction. Therefore, Oct2 is unlikely
to directly regulate Slamf1 transcription in B cells.
Examination of the pattern of expression of the Slamf1 gene
during B cell development, using the Immgen database (http:
//www.immgen.org) and by flow cytometry of bone marrow (BM)
and peripheral B cell populations indicated that Slamf1 is a marker
of B cell maturation, appearing during the transition from imma-
ture (IgMhi/IgDlo) to mature (IgMlo/IgDhi) follicular B cells of
the spleen (Figure 4D), with MZ B cells expressing intermediate
Slamf1 levels. We conclude that loss of Oct2 blocks B cell matu-
ration before the Slamf1+ stage, thereby indirectly regulating its
expression.
It has been shown that B cells lacking Slamf1 cannot form the
lasting interactions with Tfh cells that are required for GC for-
mation (51), and yet Oct2 mice do form GC upon infection and
immunization (11). We immunized WT and KO mice with SRBC
and stained GC cells for Slamf1 9 days later. Oct2+/+ and Oct2−/−
GC B cells expressed similar levels of Slamf1. This indicates that
Oct2 is dispensable for Slamf1 expression, and that endogenous
signals driving the GC response override the Oct2 maturation
defect in vivo (Figure 4E). To explore the nature of these signals,
we tested the capacity of a number of mitogens and cytokines to
induce Slamf1 expression on Oct2-null B cells in vitro. Anti-µ,
anti-CD40, Baff, and IL4, tested singly or in all possible combi-
nations, failed to induce appreciable Slamf1 on Oct2−/− B cells,
suggesting that other factors and cells contribute in vivo. Collec-
tively these studies point to an Oct2-regulated differentiation step
that enables efficient FoB cell maturation.
Obf1 ENABLES T CELL DEPENDENT ASC DIFFERENTIATION DRIVEN
BY IL4
We have shown that both Oct2 and Obf1 affect a B cell’s capacity
to differentiate to ASC in response to particular cytokines, with
Oct2 regulating the response to IL5 (29), and Obf1 being essential
for ASC differentiation driven by IL4 (52).
We determined that Obf1 lies downstream of Stat6 in the
IL4 signaling cascade (Figures 5A–C). Interestingly, while the
IL4/Stat6 axis drives both isotype switching and ASC differen-
tiation (45), Obf1 is dispensable for IL4 driven switching (52).
In order to learn how IL4 and Stat6 regulate Obf1 expression, we
performed microarray analysis on the WEHI231 B lymphoma,
an IL4 responsive line. Because Stat6 exists in a latent form in
the cytoplasm, and is activated by phosphorylation to enter the
nucleus and act as a transcription factor (53), direct Stat6 targets
would be activated after IL4 signaling even in the absence of new
protein synthesis. Cells therefore were treated with cyclohexam-
ide (CHX) to inhibit translation, and 1 h later, IL4 was added.
A parallel culture did not receive IL4. After another 4 h, RNA
was prepared from both. Analysis using Illumina Sentrix Mouse
v1.1 arrays identified a small number of genes whose expression
rose two to fourfold during this short period of IL4 stimula-
tion, genes likely to be regulated directly by Stat6. Among these
were three transcriptions factors: Nfil3, Vdr, encoding the 1,25-
dihydroxyvitamin D3 receptor, and Xbp1. Their induction under
these conditions was validated by qPCR (Figure 5D). Interestingly,
Obf1 transcription was not elevated by IL4 treatment in the pres-
ence of CHX, indicating that it is not a direct Stat6 target gene
(Figure 5D).
As Obf1 RNA is elevated by IL4 treatment in B cells in the
absence of CHX (Figure 5B), we hypothesized that one of the
three transcription factors directly regulated by Stat6 might drive
Obf1 expression. We therefore constructed ER fusion vectors for
each to determine their effects on Obf1 expression. The Xbp1-
ER expression vector contained the mature, processed, and active
form of this factor (54). Clones of each line were cultured for
24 h unstimulated, with estradiol to induce each fusion protein, or
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FIGURE 4 | Oct2 influences and Slamf1 expression in B cells. (A) Analysis
of Slamf1 expression in Oct2-null and Oct2+ /+ B cells activated in vitro. Cells
were cultured for 48 h in the presence of CpG or aCD40 before RNA was
prepared for RNA sequencing. Filled bars, Oct2+ /+ gray bars, Oct2−/−.
(B) Slamf1/CD150 protein expression in cells of the indicated genotypes.
Cells were assessed directly ex vivo (resting, top panels), or were activated
in vitro for 48 h with either LPS (B cells) or anti-CD3 (T cells). Macrophages
were expanded from fetal liver as described in Section “Materials and
Methods.” In the histograms, WT cells are represented with heavy black lines
and Oct2−/− as red. Unstained controls are indicated by thin black lines.
(C) WEHI231 cells (Oct2+ /+) and OM1 cells (Oct2−/−), either uninfected or
(Continued)
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FIGURE 4 | Continued
transduced with an Oct-ER expression vector, were cultured in the
presence or absence of estradiol (Es) for 24 h and CD36 and Slamf1 levels
were determined by flow cytometry. Thin lines indicate background
fluorescence of unstained controls, blue lines represent CD36 and Slamf1
levels in uninduced cultures, and heavy black lines, the levels after Es
induction. (D) Slamf1 expression during B cell maturation. Colors indicate
the populations represented in each histogram. For bone marrow,
recirculating B cells were B220++ and IgM+, immature B were B220+ and
IgM++, and precursor B were B220+ and IgM−. For spleen, immature B
cells were IgMhi, IgDlo, MZ B cells were IgMhi, CD21hi, and Fo B cells were
IgMlo, IgDhi, CD23+, and CD21+. Lymph node B cells were IgMlo, IgDhi, and
CD23+. (E) Flow cytometric analysis of splenic B cells from naïve and
immunized mice (9 days after SRBC immunization). Top panels show the
percentage of GL7+Fas+ GC B cells (gated) among total B220+ cells in
spleens from mice reconstituted with WT or Oct2−/− fetal liver. Bottom
panels show the Slamf1 levels on non-GC (gray lines) and GC (black line) B
cells for each animal, gated as shown in the upper panels.
with IL4. IL4 caused an increase in Obf1 RNA levels in all cases, as
expected. However, estradiol induction only increased Obf1 lev-
els significantly in the Xbp-ER expressing cell line (Figure 5E).
Finally, primary splenic B cells from Xbp1+/+, heterozygous and
conditional KO mice were stimulated for 48 h with CD40 ligand
and IL4, and protein extracts prepared. Western blots showed that
Xbp1-null B cells express markedly less Obf1 than the controls
(Figure 5F). These data indicate that Nfil3 and Vdr do not influ-
ence Obf1 expression, but that Xbp1 has the capacity to directly
activate the Obf1 gene in response to IL4/Stat6 signaling in B cells.
DISCUSSION
The data we present here adds to a growing view of Oct2 and
Obf1 as essential contributors to the sensing capacity of B cells
(Figure 6). These two factors enhance the cell’s ability to deliver
a BCR signal to drive maturation, or to sense a foreign antigen
and become activated. We show here that Oct2 may do so by
fine-tuning Syk levels. Since Oct2 loss blocks peripheral B cell
maturation, such that MZ B cells are missing and mature FoB
reduced, Oct2 may play its most important role prior to a diver-
gence point of Fo and MZ B cells (55). The immature Slamf1−,
BaffR+, CD23+, CD21+, IgMhi, Dlo, HSAhi phenotype of Oct2−/−
B cells does not neatly fit into the phenotypic transition of imma-
ture to mature B cells (55), and may represent a normally transient
phase of B cell maturation. Obf1 is required for normal B cell
maturation and MZ B cell development (33), but as Obf1 does
not influence Syk expression, it is likely that the two factors act
through unique subsets of target genes for this aspect of B cell
development. Indeed, it has been reported that Obf1 positively
regulates SpiB gene expression (56), and that SpiB is required for
normal B cell maturation and BCR signaling, through regulation
of c-rel (57, 58).
T cell dependent antibody responses depend upon Oct2 and
Obf1 in several ways. Both Oct2 and Obf1 are required for B cells to
produce normal levels of IL6, a cytokine important in Tfh matura-
tion in the context of a Slamf1-mediated B cell:Tfh cell interaction
(11, 59, 60). These molecular interactions enable the initiation of
a fruitful T cell-dependent humoral immune response. For exam-
ple, IL6 produced by activated B cells early in the GC response
reinforces the early dendritic cell signal that initiates Tfh differen-
tiation, and IL21 produced by the nascent Tfh enhances both Tfh
function and B cell differentiation into GC B cells and ASC (61–
66). Slamf1, which is indirectly dependent upon Oct2, is required
to prolong the B:Tfh interaction while these important signals are
exchanged. Subsequently, Oct2 and Obf1 enable B cells to respond
to other Th cell cytokines that drive ASC differentiation. Oct2
regulates Cd125 expression (29), and so expression of the high
affinity receptor for IL5, an ASC differentiation factor (45). Obf1
is required for a normal B cell response to IL4, a growth, survival,
isotype switching and differentiation factor for B and plasma cells
[(45, 67) and this study].
Except for the specific case of Obf1 and a subset of VL genes
(68), there is no evidence that Oct2 or Obf1 are required for Ig
gene expression or for antibody secretion in ASC generated from
single or double KO mice (29, 39, 52). Interestingly, however, we
show here that Xbp1, which is highly expressed in ASC and known
to be required for ASC function [(69–72) and our unpublished
data], can directly activate Obf1. Shen and Hendershot (73) have
also shown in ASC that Obf1 is a direct target of Xbp1. Accord-
ingly, Obf1 expression is elevated in normal ASC compared to B
cells, unlike Oct2 expression, which declines with differentiation
(Figure 1). Xbp1, normally associated with the unfolded protein
response in ASC, is an IL4 response gene in B cells. We confirm
here that Obf1 is an Xbp1 target gene in FoB cells, and that IL4 and
Stat6 directly induce Xbp1. Iwakoshi et al. (70) have earlier shown
that, in the context of ASC differentiation, IL4 strongly induces
Xbp1 expression and Stat6 is required. Thus, the selective ASC
differentiation defect in Obf1 null B cells under T cell-dependent
conditions may reflect an important Stat6-Xbp1-Obf1 axis.
Instead of direct influences on Ig gene expression, poor
humoral immune responses in Oct2 or Obf1 mutant mice more
likely reflects a paucity of differentiated peripheral B cell popu-
lations and weak to absent influences of T cells on these B cells.
Oct2 and Obf1 are most highly expressed in GC B cells, with Obf1
being essential for their differentiation, but Oct2 dispensable (11).
In both mutants, the B cells defects are cell intrinsic. Outstanding
questions remain: what are the genes that Oct2 and Obf1 reg-
ulate to ensure full peripheral maturation and competent BCR
signaling? What are the Obf1 regulated genes that are essential for
GC development under all circumstances tested so far, including
immunization, infection, and autoimmunity (11, 32, 37)? While
these critical Obf1 target(s) are not yet known, candidates such
as Bcl6 (or its co-repressor MTA3), Bach2, Irf4 and CXCR5, all
critical for normal GC formation or maintenance [see Ref. (74)],
can be excluded, as they are not influenced by Obf1 loss (our
unpublished data). Ongoing genome-wide RNA expression analy-
sis, coupled with ChIPseq, will enable detailed characterization of
the full Oct2 and Obf1 gene regulatory networks, and their shared
and unique responsibilities in delivering effective B cell immunity.
MATERIALS AND METHODS
CELL LINES, CELL CULTURE, AND RETROVIRAL TRANSDUCTION
B lymphoma cell lines used here were all generated in house:
WEHI231 (75), BC1, and OM1 (48). Primary splenic B and T
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FIGURE 5 | Obf1 is downstream of Stat6 in the IL4 signaling
cascade. (A) Western blots to detect Obf1 and Stat6 proteins in purified
B cells of the indicated genotypes, harvested 48 h after anti-CD40± IL4
treatment. Actin is included as a loading control. (B) RNA sequencing
data showing Obf1 expression 48 h after anti-CD40± IL4 treatment in
WT (black bars) and Stat6−/− B cells (gray bars). (C) Western blot on the
same samples as in (B), to detect Stat6 and Obf1 proteins. (D) Induction
of IL4 responsive genes in the presence of the translational inhibitor
cycloheximide (CHX), as measured by qPCR. (E) Induction of Obf1 RNA
levels in B lymphoma cell lines each expressing a ER fusion of each of
the transcriptional regulators that are direct IL4 target genes: Nfil3, Vdr,
and Xbp1. Cells were untreated or treated with either estradiol or IL4 for
24 h. In (B,D,E), values are means±SD for triplicate samples.
(F) Western blot to detect Obf1 protein in purified B cells from Xbp1+ /+,
heterozygous, or conditional KO mice. Cells were cultured in anti-CD40
plus IL4 for 48 h before analysis. In (B,D,E), means±SD for triplicate
measurements are shown, with P values determined using the unpaired
Student’s t -test. NS, not significant.
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FIGURE 6 | Oct2 and Obf1: finessing the B cell. Summary of published
work and data discussed here, identifying the B cell responses that depend
upon Oct2 and Obf1 for their optimal function. Oct2 (red arrow) selectively
enables B cells to respond to IL5, a T cell-derived driver of ASC
differentiation (45). Obf1 (blue arrow) selectively mediates IL4 driven ASC
differentiation, downstream of Stat6. Both Oct2 and Obf1 (green arrows)
enable BCR signaling, B cell maturation and indirectly, expression of
Slamf1, an important mediator of B cell:T cell interactions during a humoral
immune response.
cells were purified using anti-B220 or anti-CD4 microbeads (Mil-
tenyi), as described (11). Oct2+/+ and Oct2−/−macrophages were
expanded in vitro from E13 fetal liver using M-CSF, as described
(15). Retroviral transduction in all cases used the pMX-pie vector
and was preformed using spin infection as described (48, 76). For
lymphoma lines, cells were cloned post-infection as single GFP+
cells in puromycin-supplemented medium.
For the retroviral complementation experiment of Figure 3E,
primary splenic B220+ cells were stimulated for 24 h with
CpG [1µM oligonucleotide CpG 1668 (sequence 5′-TCCATGA
CGTTCCTGATGCT-3′), fully phosphothioated GeneWorks] to
promote cell cycling and enable retroviral infection. After
overnight culture, cells were washed and resuspended in
medium at 0.5× 106 cells/ml, without CpG but containing anti-µ
[10µg/ml AffiniPure F(ab′)2 fragment, goat anti mouse Jack-
son Laboratories] and/or Baff (250 ng/ml a kind gift from
Jürg Tschopp). Cell survival in transduced (GFP+) cells was
assessed after a further 48 h by flow cytometry, propidium
iodide exclusion, and cell counting using internal microbead
controls.
Retroviruses expressing transcription factors fused to the
human estrogen receptor (hER) dimerization domain were gen-
erated by amplification of each factor’s ORF, and sequencing each
amplified product to ensure it was mutation-free and in frame
with the hER. Production of ER fusion proteins of the correct size
was confirmed by western blots of infected or transfected cells.
Anti-CD40 (clone FGK4.5) was prepared in house and used at
10µg/ml. β-Estradiol (Sigma) was used at 10µM, cycloheximide
at 50µM.
MICE
Oct2−/−, Obf1−/−, and Stat6−/− mice have been described previ-
ously (19, 36) Xbp1fl/flCd19Cre/+mice, where Xbp1 is conditionally
deleted in the B cell lineage, were generated by Hetz et al. (77) and
further described in Taubenheim et al. (72). All mice were main-
tained on a C57BL/6 background, and all experiments conformed
to the relevant regulatory standards of the Animal Ethics Com-
mittee of the Walter and Eliza Hall Institute of Medical Research
(AEC Projects 2010.010 and 2013.014).
ANTIBODIES
For westerns, antibodies used were specific for Oct2 (clone 9A2,
in house), Obf1 (clone 6F10, in house) Stat6 (S-20), Syk (N-
19), and actin (I-19) all from Santa Cruz and Xbp1 (Ab37152-
100, Abcam). For flow cytometry, antibodies used were specific
for B220 (RA3-6B2), IgD (11-26c.2a), fas/CD95 (Jo2), all from
BD Pharmingen Slamf1/CD150 (TC15-12 F12.2, Biolegend), and
GL7 (eBioscience). Calcium flux was assessed cytometrically as
described (78).
MICROARRAYS
Illumina Sentrix Mouse v1.1 arrays were probed with RNA pre-
pared from independent B lymphoma cell lines: to identify Oct2-
dependent genes, two independent clones of OM1 cells stably
transduced with a control vector or one expressing an estradiol-
inducible Oct-ER fusion protein were treated in vitro for 6 or 48 h
with estradiol prior to RNA preparation. For Obf1 targets, two
clones of the Obf1−/− BM1 lymphoma line (78), transduced with
vector control or an Obf1-ER expression vector, were induced in a
similar manner and RNA prepared and analyzed.
RNA SEQUENCING
Peripheral B cell populations were sorted from naïve or immu-
nized C57Bl/6 mice as described in the legend to Figure 1. Two
independent biological replicates were prepared for each popu-
lation, except for spleen and BM ASC. Because of the paucity of
ASC in these tissues, cells were pooled from three to four individ-
uals before sorting. Two such pools were processed independently
for sequencing. Normalized expression levels are shown in the
graphs. As more than 70% of reads in RNA from ASC map to
the Ig loci, all Ig reads were excluded from the data, for all pop-
ulations, before normalization to generate the values shown in
Figure 1A. Specifically, all reads from the IgH locus on chromo-
some 12, NC_000078.6 (positions 113,258,768–116,009,954), all
reads from the Igλ locus on chromosome 16, NC_000082.6 (posi-
tions 19,026,858–19,260,844), and all reads from the Igκ locus on
chromosome 6, NC_000072.6 (positions 67,555,636–70,726,754)
were excluded. For Figure 2B, Oct2+/+ and Oct2−/− B cells were
sorted, as in Figure 2A, from spleen of two independent mice of
each genotype and activated for 48 h before RNA extraction and
preparation for sequencing. As these conditions do not induce ASC
differentiation, Ig sequence reads were not excluded from analysis
of these samples.
PRIMERS
The starts of Syk transcription in primary B cells were deter-
mined directly using FirstChoice® RLM-RACE (Ambion) and
nested Syk gene specific primers specific for the first Syk coding
exon: 5′-GTAGGTCAGGTGGTTGGCGCTGTCCACAGC-3′ and
5′-CCCGCCATGTCTGCACCCCTTCAGAGTTC-3′.
For exon-specific Syk qPCR, these primers were used:
5′Syk exon 1: 5′-CAGTGACTGCGGCTGAGCGCGGACC-3′
5′Syk exon 2: 5′-CAGCAGGAAACCTCCACTTGCTCTCC-3′
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Common 3′ Syk primer: 5′-CCATGTCTGCACCCCTTCAGAG
TTC-3′.
For Syk ChIP PCR, these primers were used:
Exon 2: fwd 5′-GCCTAGGCCACGATGGTCAAAGGAGG-3′ and
rev 5′-GGAGAGCAAGTGGAGGTTTCCTGCTG-3′.
Upstream of exon 2: fwd 5′-CCATTGGTGGGCCCTCAGCTTG
GTTC-3′ and
rev 5′-GACCAGAGAAGAAATGGCCTCAGAAGACAGG-3′.
Chromatin immunoprecipitation was conducted as previously
described (29), using high titer, polyclonal anti-Oct2 rabbit serum
generated in house.
Primers for other qPCR were:
Stat6: fwd 5′-CTGCTGGGCCGAGGCTTCACATTT-3′
rev 5′-TCAGGGGCCATTCCAAGATCATAAGGT-3′
CD36 : fwd 5′-GGAGGCATTCTCATGCCAGTCGGAGAC-3′
rev 5′-CAAAACTGTCTGTACACAGTGGTGCCTG-3′
Slamf1: fwd 5′-GGGAGCTATCCAGATCACCTG-3′
rev 5′-CGTTCTCCTCCACGCTCAC-3′
Cd23: fwd 5′-GACACTGCAATTCAGAATGTCTCTCATG-3′
rev 5′-GCTTCTGTTCAGCTTGGAGTTCTTGCAAG-3′
Nflil3: fwd 5′-CTCACGGACCAGGGAGCAGAACCACG-3′
rev 5′-CAGGTCTTAAGGACTTCAGCCTCTCATCC-3′
Obf1: fwd 5′-CGGTGTTGACCTATGCTTCTCCACC-3′
rev 5′-GAGGGGCGCCTGGTGCTCGGGACCC-3′
Vdr: fwd 5′-CGCTATGACCTGTGAAGGCTGCAAGGG-3′
rev 5′-GCCAATGTCCACGCAGCGTTTGAGCC-3′
Xbp1: fwd 5′-AGCAGCAAGTGGTGGATTTG-3′
rev 5′-CCAAGCGTGTTCTTAACTCCT-3′
Hmbs (for normalization): fwd 5′-GACCTGGTTGTTCACTCC
CTGAAG-3′
rev 5′-GACAACAGCATCACAAGGGTTTTC-3′
Chromatin immunoprecipitation PCR and qPCR were per-
formed on triplicate samples in all cases, and the data presented
as means± SD. Statistical significance was determined using the
unpaired Student’s t -test.
IMMUNIZATION
Mice stably reconstituted with Oct2+/+ or Oct2−/− fetal liver
were immunized i.p with 2× 109 sheep red blood cells (Applied
Biological Product Management, Australia) in 100µl of PBS and
sacrificed after 9 days.
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